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Summary
Background: Clinical outcome of patients with head and neck
squamous cell carcinoma (SCCHN) depends on several risk
factors like the presence of locoregional lymph node or dis-
tant metastases, stage, localisation and histologic differentia-
tion of the tumour. Circulating tumour cells in the bone mar-
row indicate a poor prognosis for patients with various kinds
of malignoma. The present study examines the clinical rele-
vance of occult tumour cells in patients suffering from
SCCHN. Patients and Methods: Bone marrow aspirates of 176
patients suffering from SCCHN were obtained prior to surgery
and stained for the presence of disseminated tumour cells.
Antibodies for cytokeratin 19 were used for immunohisto-
chemical detection with APAAP on cytospin slides. Within a
clinical follow-up protocol over a period of 60 months, the
prognostic relevance of several clinicopathological parame-
ters and occult tumour cells was evaluated. Results: Single
CK19-expressing tumour cells could be detected in the bone
marrow of 30.7% of the patients. There is a significant correla-
tion between occult tumour cells in the bone marrow and re-
lapse. Uni- and multivariate analysis of all clinical data
showed the metastases in the locoregional lymph system and
detection of disseminated tumour cells in the bone marrow to
be statistically highly significant for clinical prognosis. Con-
clusion: The detection of minimal residual disease underlines
the understanding of SCCHN as a systemic disease. Further
examination of such cells will lead to a better understanding
of the tumour biology, as well as to improvement of diagnos-
tic and therapeutic strategies.
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Zusammenfassung
Hintergrund: Der klinische Verlauf und die Prognose von Pa-
tienten mit Plattenepithelkarzinomen des Kopf-Hals-Bereiches
(SCCHN) sind von vielen Risikofaktoren abhängig, wie dem
Befall der lokoregionären Lymphabflusswege, Stadium, Loka-
lisation und Differenzierungsgrad des Primärtumors sowie
dem Auftreten von Fernmetastasen. Die vorliegende Studie
untersucht die klinische Relevanz der systemischen Verbrei-
tung einzelner Tumorzellen im Knochenmark, die für eine
Reihe von anderen Tumorentitäten als negativer Prognosefak-
tor beschrieben wurde, bei Patienten mit SCCHN. Patienten
und Methoden: Nach schriftlichem Einverständnis wurden
präoperativ Knochenmarksaspirate von 176 Patienten mit
SCCHN entnommen und untersucht. Mittels monoklonaler
Antikörper gegen Zytokeratin 19 (CK19) wurden die dissemi-
nierten Tumorzellen auf Zytospin Präparaten immunhistoche-
misch angefärbt. Mit Hilfe eines klinischen Nachsorgeproto-
kolls konnten die klinischen Daten während der folgenden 
5 Jahre erhoben werden. Ergebnisse: Bei 30,7% der Patienten
mit SCCHN konnten einzelne CK19 exprimierende Tumorzel-
len im Knochenmark nachgewiesen werden. Es bestand eine
signifikante Korrelation zwischen dem Nachweis CK19-positi-
ver Zellen und einem Rezidiv. In einer uni- und multivariaten
Analyse aller klinischen Daten erwies sich der Nachweis
okkulter Tumorzellen im Knochenmark, sowie der Befall der
lokoregionären Lymphknoten als signifikant für die klinische
Prognose. Schlussfolgerungen: Die Daten der vorliegenden
Studie beweisen eine systemische Verbreitung von Tumorzel-
len in den Blutkreislauf bei Patienten mit SCCHN mit erhebli-
chem Einfluss auf den Verlauf der Erkrankung. Der Nachweis
der minimal residualen Tumorerkrankung unterstreicht, dass
Plattenepithelkarzinome des Kopf-Hals-Bereichs als systemi-
sche Erkrankung anzusehen sind. Die weitere Untersuchung
solcher disseminierter Tumorzellen wird zu einem verbesser-
ten Verständnis der Tumorbiologie und zu neuen diagnosti-
schen sowie therapeutischen Möglichkeiten führen.
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Introduction
Patients suffering from squamous cell carcinoma of the head
and neck (SCCHN) are at high risk to develop local recur-
rences or distant metastases. Depending on stage and localisa-
tion of the tumour, the risk for local relapse is higher than
50%. The development of distant metastases of SCCHN oc-
curs in 15–25% of the patients, although the true incidence
might be even higher as described in several autopsy studies
[1, 2]. Early detection of disseminated tumour cells is tedious,
because SCCHN metastasizes lymphogenously, implicating
only a very low number of circulating tumour cells to be pre-
sent in hematogenous compartments like peripheral blood
and bone marrow [3].
The cytoskeleton of epithelial cells contains intermediate-
sized filaments which are composed of characteristic cytoker-
atins. Since neoplastic cells retain the main cytoskeletal prop-
erties of their progenitors, cytokeratins are found in normal as
well as in malignant epithelia [4]. Here we examine cytoker-
atin 19 (CK19), which is expressed in most simple epithelia, in
cultured keratinocytes and in normal and malignant squamous
epithelia, for the detection of disseminated tumour cells in
bone marrow of patients. Expression of cytokeratins is re-
stricted to epithelial cells, which, in healthy persons, are absent
from hematogenous compartments like peripheral blood or
bone marrow. The detection of CK19 in peripheral blood and
bone marrow of patients suffering from epithelial malignoma
may therefore indicate the unphysiological presence of epithe-
lial cells, which might be caused by the spread of the respec-
tive malignoma. As CK19-expressing cells are lacking in the
bone marrow of healthy donors, these cells are highly likely to
represent disseminated tumour cells. Therefore, we chose the
bone marrow, an exclusively mesenchymal organ which repre-
sents a defined medium for the detection of single circulating
cancer cells, for the diagnosis of disseminated disease in pa-
tients suffering from SCCHN.
The aim of the study was to evaluate the prognostic signifi-
cance of CK19-expressing tumour cells in bone marrow for
clinical outcome of patients with SCCHN. Our approach may
help to detect a new prognostic marker to select those patients
who are at high risk to develop local or distant recurrence. By
the application of adjuvant systemic and multimodal thera-
pies, as well as by carrying out further examinations it might
be possible to improve the prognosis for those patients.
Patients and Methods
Patients
Patients with histologically defined SCCHN of various sites (n = 176)
were recruited and followed for 60 months. Tumour stage and grading
were determined according to the TNM classification [5]. All patients un-
derwent surgery for removal of the tumour. Patients with higher tumour
stages received subsequent radiotherapy. During follow-up, patients initi-
ally were investigated every 3 months and after 1 year every 6 months.
Clinical observation included physiological examination, chest X-ray, en-
doscopy, ultrasound, routine bone scintigraphy and CT scan in cases of
specific suspect. In the grading, disease-free survival was defined as survi-
val without recurrence or distant metastases or second primary cancer. 
5-year survival rates were analysed in all patients. 
Bone Marrow Aspirates, Preparation and Immunohistological 
Investigation
After written informed consent, bone marrow aspirates from patients
with SCCHN were taken prior to surgery from both iliac crests in heparin-
coated syringes. In order to avoid displacement of epidermal cells into the
sample, aspiration was performed through a small cut in the skin. Aspira-
tes were separated through Ficoll/Hypaque density centrifugation accor-
ding to standard protocol [6]. Cytospin preparations were prepared with 
5 × 105 cells per glass slide. From each patient 2 × 106 nucleated cells were
examined.
CK19 expression was detected immunohistochemically by the APAAP
method [7], using the monoclonal KS 19.1 antibody (Progen, Heidelberg,
Germany) against CK19, at a concentration of 5 µg/ml. Specifically bound
antibody was visualised by staining with newfuchsin (5% in 2N HCl). Cell-
nuclei were counterstained with hemalaun (Merck, Darmstadt, Germany).
Endogenous alkaline phosphatase activity was blocked by incubation with
levamisole. Bone marrow samples were classified CK19 positive if one or
more cells clearly stained red could be identified. Bone marrow samples of
healthy donors served as negative controls, whereas FaDu cells (pharynge-
al squamous cell carcinoma, ATCC, Rockville, MD, USA) served as posi-
tive controls. For isotype control two slides of each patient and normal
volunteer were incubated with mAb IgG2aκ (No. M-9411, Sigma Immu-
nochemicals, Deisenhofen, Germany) in an appropriate concentration.
Statistical Analysis
The chi-square test was employed to evaluate correlations between the
presence of CK19-positive cells in bone marrow and relapse as well as the
clinicopathological parameters. Cox proportional hazards model [8] was
applied for uni- and multivariate analysis, using the program BMDP2L.
The Kaplan-Meier method [9] was used to determine survival rates. Statis-
tical significance was calculated with the use of the log-rank test and de-
noted by p values lower than 0.02.
Results
CK19-Expressing Tumour Cells in Patients’ Bone Marrow
Samples and Clinical Parameters
In 54 of 176 bone marrow samples (30.7%) of patients with
SCCHN of various sites, CK19-expressing tumour cells could
be detected. Bone marrow samples of all healthy volunteers
and all isotype controls showed no CK19 expression. The de-
tection of occult tumour cells increased with the size of the
primary tumour and with advanced lymph node involvement
resulting in higher UICC stages. Histological grading and lo-
calisation did not influence the incidence of tumour cells. Sta-
tistically, there was no difference between patients with or
without tumour cells in the bone marrow within the basic clin-
ical parameters (table 1).
CK19-Expressing Tumour Cells in Bone Marrow and Tumour
Recurrence
Applying a clinical follow-up protocol, 176 patients were fol-
lowed over a period of 5 years, which is the critical threshold
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for survival in SCCHN. During the follow-up time 60 patients
(34.09%) developed recurrent disease: 34 patients (56.67%)
developed locoregional recurrences and 26 (43.33%) present-
ed with distant metastases. The presence of occult tumour
cells in the bone marrow was tightly associated with recurrent
disease. 50% (27/54) of patients with CK19-positive cells in
the bone marrow relapsed (locoregional or distant (combined
recurrence noted under distant metastases)) compared to only
27.05% (33/122) without. Statistical evaluation lead to a sig-
nificant correlation with p = 0.003. 
Prognostic Relevance of Clinicopathological Parameters and
CK19-Expressing Tumour Cells in the Bone Marrow
Applying a multivariate or univariate analysis of clinical para-
meters and the presence of occult tumour cells in the bone
marrow the prognostic relevance for overall survival was most
significantly affected by lymph node involvement (p = 0.0001)
and the presence of CK19-expressing, disseminated tumour
cells in the bone marrow (p = 0.0066) (table 2).
Univariate consideration identified lymph node involvement
(p = 0.0001), CK19 positivity of the bone marrow (p = 0.0124)
and late UICC stages of disease (p = 0.0173) as significant risk
factors in SCCHN, whereas no relevance could be detected
for the tumour size (p = 0.1033) and differentiation of the 
tumour (p = 0.2243) (table 3). 
Discussion
Over the last decade, circulating tumour cells in the bone mar-
row have gained increasing prognostic relevance in various
kinds of solid malignoma. Many studies have demonstrated a
significant correlation between the presence of disseminated
tumour cells in secondary organs, such as the bone marrow,
peripheral blood or lymph nodes and a high risk for local re-
lapse, distant metastases and a shortened overall survival in
patients with breast and colorectal cancer [10–12]. Further-
more, it has been shown that detection of those cells with im-
munohistochemical and molecular techniques is feasible
[13–16]. 
The aim of the present study was to examine the prognostic
significance of circulating tumour cells present in the bone
marrow of patients with SCCHN. In a comparison of all stan-
dard clinical data with the presence of occult tumour cells, sig-
nificant parameters should be established to distinguish those
patients with a high risk to develop local or distant relapse.
In the present study monoclonal antibodies directed against
CK19 were applied for the diagnosis of occult carcinoma cells.
CK19-expressing tumour cells were detectable in the bone
marrow of 30.68% of patients; 50% of these patients relapsed,
compared with only 27.05% without CK19-positive cells in the
bone marrow. Further, statistical evaluation led to a signifi-
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Parameter All patients, n CK19+ patients CK19– patients p Value
 
n % n %
UICC-stage
UICC1/2 60 15 25.00 45 75.00
UICC3/4 116 39 33.62 77 66.38
0.240
Tumor extension
pT1 44 10 22.73 34 77.27
pT2 60 19 31.67 41 68.33
pT3 43 15 34.88 28 65.12
0.595
pT4 29 10 34.48 19 65.52
Lymph node
involvement
pN0 88 27 30.68 61 69.32
pN1 31 8 25.81 23 74.19
pN2 50 16 32.00 34 68.00
0.831
pN3 7 3 42.86 4 57.14
Localisation
Oral cavity 37 10 27.03 27 72.97
Oropharynx 43 11 25.58 32 74.42
Larynx 68 22 32.35 46 67.65
0.610
Hypopharynx 28 11 39.29 17 60.71
Grading
G0 7 2 28.57 5 71.43
G1 94 31 32.98 63 67.02
G2 73 21 28.77 52 71.23
0.739
G3 2 0 2 100.00





Table 1. Correlation of clinical parameters
with the presence of CK19-expressing tumour
cells in the bone marrow 
cant correlation between CK19 positivity of the bone marrow
and the incidence of relapse (p = 0.003). These results indi-
cate that patients with CK19-positive bone marrow have a
higher risk for the development of recurrent disease than
those patients with CK19-negative bone marrow. In a univari-
ate and multivariate statistical analysis the detection of occult
tumour cells in the bone marrow showed to be statistically as
valid as locoregional metastases for the prediction of clinical
outcome of the disease. Tumour spread to the locoregional
lymph nodes is the most significant risk factor, in univariate 
(p = 0.0001) as well as multivariate (p = 0.0001) analysis. Fur-
ther, the presence of occult tumour cells in the bone marrow
was found to be relevant as an univariate (p = 0.0124) and
multivariate (p = 0.0066) parameter whereas UICC stage of
the disease (p = 0.0173) appeared to be significant only in uni-
variate analysis. 
SCCHN metastasize in lymphogenous ways, frequently using
clinically undiscovered, complex pathways of the locoregional
lymphatic vessels [17]. Distant metastases frequently occur in
lung, liver and skeleton in 15–25% of the patients following
first therapy. To date, the true incidence of distant metastases
remains unclear as autopsy studies report an incidence of
40–57% [18, 19]. The minimal residual disease of occult tu-
mour cells remaining in locoregional lymphatic vessels or dis-
tant organ systems poses the major problem and documents
that SCCHN is a systemic disease.
Expecting ubiquitous spread of occult tumour cells, the pe-
ripheral blood should be very suitable for the detection of
such cells. However, although detection methods have been
improved very much over the years, the use of occult tumour
cells in the blood as surrogate marker for validation of new
therapeutic strategies is limited. Due to different spreading ki-
netics and the diluting effect of the total blood volume, cap-
turing an adequate amount of tumour cells in a small blood
sample is difficult and probably does not reflect the true situa-
tion. The bone marrow is easily accessible and thought to
function as an extra filter for occult tumour cells, although
bone metastases are rare in SCCHN. In this study we per-
formed bone marrow aspiration from patients both iliac crests.
This seems quite suitable, since in adults the highest coherent
amount of active haematopoietic bone marrow (one third) is
located in the pelvis and examination of bone marrow aspi-
rates derived from the iliac crests gives view to a large propor-
tion of the whole bone marrow. However, as shown in the lit-
erature the detection rate of disseminated tumour cells in-
creases proportionally with the increase of bone marrow aspi-
ration sites. In future, use of a larger number of puncture sites
might improve the detection rate of tumour cells in patients’
bone marrow [20]. Earlier publications document that as few
as 1–3 tumour cells in a million bone marrow cells can be de-
tected in patients with SCCHN [21–23].
The techniques for the detection of micrometastatic cells
cover different methods and vary in their sensitivity and the
specificity of the marker used. Several groups already demon-
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strated that the use of cytokeratins as markers for disseminat-
ed disease in the bone marrow is associated with difficulties,
which on the one hand depends on the technique applied for
detection, on the other hand on the species of cancer and the
cytokeratin investigated [24].
Immunohistochemistry is most widespread in the diagnosis of
occult carcinoma cells, since it allows visualisation of the de-
tected cells. However, immunohistochemical examination of
bone marrow samples sometimes might be affected by cross
reactions between the antibodies and Fc receptors expressed
on progenitor cells or immunocytes like macrophages, which
are present in the bone marrow and which might cause false
positive results. Control stains of healthy bone marrow donors
are necessary to safely set up the technique.
Through applying molecular methods like RT-PCR (reverse
transcriptase polymerase chain reaction) sensitivity of im-
munohistochemical detection can be raised. Theoretically this
method offers the possibility to detect single RNA molecules,
so that it seems especially suitable to detect very low numbers
of cells [25]. On the other hand, such a high sensitivity may
also detect low illegitimate or ectopic expression levels of
some molecules and thereby may cause false positive results
[26–28]. Using CK19 as marker for RT-PCR-based detection
of occult tumour cells in the bone marrow of cancer patients,
one also has to be aware of the known existence of pseudo-
genes as well as of low levels of CK19 expressed by stromal
cells which are present in the bone marrow.
Further studies will cover examination of biological behaviour
of occult tumour cells. Characterising migratory behaviour,
Table 2. Correlation between relapse, metastases and CK19-expressing
tumour cells in the bone marrow
Total, n Relapse Metastases
 
n % n %  
CK19+ Patients 54 27 50 13 24.07  
CK19– Patients 122 33 27.05 14 11.48  
p Value 0.003 0.032
Table 3. Prognostic relevance of clinicopathological parameters and
CK19-expressing tumour cells in the bone marrow – univariate and multi-
variate consideration
Parameter Univariate Multivariate
analysis, p analysis, p
Lymph node state 0.0001 0.0001  
CK19-positive bone marrow 0.0124 0.0066  
UICC stage of disease 0.0173 0.2863  
Tumour size 0.1033 0.1483  
Histological differentiation 0.2243 0.9243 
of the tumour
phenotypic and growth characteristics as well as expansion of
circulating human tumour cells may widen the possibilities for
a morphological and genetic characterisation of disseminated
disease in SCCHN and thus lead to new immunotherapeutic
strategies [28, 29].
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